Role of Tissue-Resident Memory in Intra-Tumor Heterogeneity and Response to Immune Checkpoint Blockade

Role of Tissue-Resident Memory in Intra-Tumor Heterogeneity and Response to Immune Checkpoint Blockade

Tissue-resident memory T (TRM) cells are a distinct subset of memory T cells that reside in non-lymphoid tissues for prolonged periods of time without significant recirculation providing continued immune surveillance at these sites. Recent studies suggest that TRM cells are also enriched within tumo...

Full description

Bibliographic Details
Main Author:	Kavita M. Dhodapkar
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2018-07-01
Series:	Frontiers in Immunology
Subjects:	tissue-resident memory cells immune checkpoint blockade tumor heterogeneity cancer immunotherapy immunity to cancer
Online Access:	https://www.frontiersin.org/article/10.3389/fimmu.2018.01655/full

Similar Items

MTHFR act as a potential cancer biomarker in immune checkpoints blockades, heterogeneity, tumor microenvironment and immune infiltration
by: Jianheng Peng, et al.
Published: (2023-06-01)

Limited Predictive or Prognostic Role of Tumor-Infiltrating Tissue-Resident Memory CD8 T Cells in Patients with Hepatocellular Carcinoma Receiving Immunotherapy
by: Ying-Chun Shen, et al.
Published: (2021-10-01)

Editorial: Factors determining long term anti-tumor responses to immune checkpoint blockade therapy
by: Roberta Zappasodi, et al.
Published: (2022-12-01)

Modern cancer therapy: cryoablation meets immune checkpoint blockade
by: Qi Liu, et al.
Published: (2024-02-01)

Overcoming melanoma resistance to immune checkpoint blockade therapy using nano-strategies
by: Yiqin Ding, et al.
Published: (2023-12-01)

The current landscape of predictive and prognostic biomarkers for immune checkpoint blockade in ovarian cancer
by: Yufei Xu, et al.
Published: (2022-10-01)

Photothermal therapies to improve immune checkpoint blockade for cancer
by: Preethi B. Balakrishnan, et al.
Published: (2020-12-01)

Tissue-resident memory T cells in immune-related adverse events: friend or foe?
by: Robin Reschke, et al.
Published: (2023-12-01)

Editorial: HIV and Cancer Immunotherapy: Similar Challenges and Converging Approaches
by: Mirko Paiardini, et al.
Published: (2020-03-01)

Tissue-resident memory T cells in the era of (Neo) adjuvant melanoma management
by: Kai R. Plunkett, et al.
Published: (2022-11-01)

Immune responses to SARS-CoV-2 in vaccinated patients receiving checkpoint blockade immunotherapy for cancer
by: Alexander Piening, et al.
Published: (2022-12-01)

Coinhibitory Receptor Expression and Immune Checkpoint Blockade: Maintaining a Balance in CD8+ T Cell Responses to Chronic Viral Infections and Cancer
by: Isobel S. Okoye, et al.
Published: (2017-09-01)

Heterogeneity of the tumor immune microenvironment and its clinical relevance
by: Qingzhu Jia, et al.
Published: (2022-04-01)

Age-Related Differences in Molecular Profiles for Immune Checkpoint Blockade Therapy
by: Qi-jie Zhang, et al.
Published: (2021-04-01)

Checkpoint Blockade Toxicity and Immune Homeostasis in the Gastrointestinal Tract
by: Michael Dougan
Published: (2017-11-01)

The Tumor Microenvironment in the Response to Immune Checkpoint Blockade Therapies
by: Florent Petitprez, et al.
Published: (2020-05-01)

bITH, a blood-based metric of intratumor heterogeneity, is associated with clinical response to immune checkpoint blockade in non-small cell lung cancerResearch in context
by: Yun Fan, et al.
Published: (2023-05-01)

Progress and Challenges of Predictive Biomarkers for Immune Checkpoint Blockade
by: Yanna Lei, et al.
Published: (2021-03-01)

Recent Advances of Immune Checkpoint Inhibition and Potential for (Combined) TIGIT Blockade as a New Strategy for Malignant Pleural Mesothelioma
by: Sophie Rovers, et al.
Published: (2022-03-01)

Towards a precision immune checkpoint blockade immunotherapy in patients with colorectal cancer: Strategies and perspectives
by: Guanglin Cui
Published: (2022-05-01)

Leveraging Endogenous Dendritic Cells to Enhance the Therapeutic Efficacy of Adoptive T-Cell Therapy and Checkpoint Blockade
by: Mie Linder Hübbe, et al.
Published: (2020-09-01)

Significance of CD103+ tissue-resident memory T cells for predicting the effectiveness of immune checkpoint inhibitors in esophageal cancer
by: Seiji Natsuki, et al.
Published: (2023-10-01)

The Role of Immune Checkpoint Blockade in the Hepatocellular Carcinoma: A Review of Clinical Trials
by: Muhammet Ozer, et al.
Published: (2021-12-01)

Characterization of genetics in patients with mucosal melanoma treated with immune checkpoint blockade
by: Elizabeth I. Buchbinder, et al.
Published: (2021-04-01)

Systematic Assessment of Transcriptomic Biomarkers for Immune Checkpoint Blockade Response in Cancer Immunotherapy
by: Shangqin Sun, et al.
Published: (2021-04-01)

Radiation combines with immune checkpoint blockade to enhance T cell priming in a murine model of poorly immunogenic pancreatic cancer
by: Courtney T. Stump, et al.
Published: (2021-11-01)

An unsuspected complication with immune checkpoint blockade: a case report
by: Lucia Carril-Ajuria, et al.
Published: (2018-09-01)

Role of medical imaging for immune checkpoint blockade therapy: From response assessment to prognosis prediction
by: Hong Wei, et al.
Published: (2019-09-01)

Recent Advances in Glioma Therapy: Combining Vascular Normalization and Immune Checkpoint Blockade
by: Rachel L. Y. Ho, et al.
Published: (2021-07-01)

Clonal tracing reveals diverse patterns of response to immune checkpoint blockade
by: Shengqing Stan Gu, et al.
Published: (2020-10-01)

Immune Checkpoint Blockade in HER2-Positive Breast Cancer: What Role in Early Disease Setting?
by: Cinzia Solinas, et al.
Published: (2021-04-01)

Immune Checkpoint Blockades in Triple-Negative Breast Cancer: Current State and Molecular Mechanisms of Resistance
by: Hyungjoo Kim, et al.
Published: (2022-05-01)

A Combination of Biomarkers Predict Response to Immune Checkpoint Blockade Therapy in Non-Small Cell Lung Cancer
by: Zedong Jiang, et al.
Published: (2021-12-01)

Tissue-resident memory T cells orchestrate tumour-immune equilibrium
by: Simone L. Park, et al.
Published: (2019-04-01)

Utilization of hypoxia-derived gene signatures to predict clinical outcomes and immune checkpoint blockade therapy responses in prostate cancer
by: Minhua Chen, et al.
Published: (2022-08-01)

Combination of DNA Vaccine and Immune Checkpoint Blockades Improves the Immune Response in an Orthotopic Unresectable Glioblastoma Model
by: Mathilde Bausart, et al.
Published: (2022-05-01)

Combination immune checkpoint blockade as an effective therapy for mesothelioma
by: Vanessa S. Fear, et al.
Published: (2018-10-01)

The Emerging Interplay Between Recirculating and Tissue-Resident Memory T Cells in Cancer Immunity: Lessons Learned From PD-1/PD-L1 Blockade Therapy and Remaining Gaps
by: Silvia Gitto, et al.
Published: (2021-11-01)

The Current Landscape of Immune Checkpoint Blockade in Metastatic Lung Squamous Cell Carcinoma
by: Hong Yuan, et al.
Published: (2021-03-01)

Mechanisms of tumor resistance to immune checkpoint blockade and combination strategies to overcome resistance
by: Xiaoting Zhou, et al.
Published: (2022-09-01)